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Abstract
Background: Neoadjuvant chemotherapy (NACT) is a standard approach of the multidisciplinary treatment of breast
cancer. Depending on the biological subtype a pathological complete response in the breast (bpCR) can be achieved
in up to 60% of the patients. However, only limited accuracy can be reached when using imaging for prediction of
bpCR prior to surgery. Due to this diagnostic uncertainty, surgery after NACT is considered to be obligatory for all
patients in order to either completely remove residual disease or to diagnose a bpCR histologically. The purpose of this
trial is to evaluate the accuracy of a vacuum-assisted biopsy (VAB) to diagnose a bpCR after NACT prior to surgery.
Methods: This study is a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. The
study will take place at 21 trial sites in Germany. Six hundred female patients with breast cancer after completed NACT
showing at least a partial response to NACT treatment will be enrolled. A vacuum-assisted biopsy (VAB) guided either
by ultrasound or mammography will be performed followed by histopathological evaluation of the VAB specimen
before standard, guideline-adherent breast surgery. The study is designed to prove that the false negative rate of the
VAB is below 10%.
Discussion: As a bpCR is becoming a more frequent result after NACT, the question arises whether breast surgery is
therapeutically necessary in such cases. To study this subject further, it will be crucial to develop a reliable test to
diagnose a bpCR without surgery.
During the study we anticipate possible problems in patient recruitment as the VAB intervention does not provide
participating patients with any personal benefit. Hence, a proficient informed consent discussion with the patient and a
detailed explanation of the study aim will be crucial for patient recruitment. Another critical issue is the
histopathological VAB evaluation of a non-tumorous specimen as this may have been taken either from the former
tumor region (bpCR) or outside of the (former) tumor region (non-representative VAB, sampling error).
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Background
Neoadjuvant chemotherapy (NACT) is a standard part of
the multidisciplinary treatment of breast cancer [1]. Now-
adays up to 30% of all breast cancer patients receive NACT
[2]. NACT has been shown to be equivalent to adjuvant
chemotherapy in terms of disease free, distant disease-free,
and overall survival in several clinical trials and enables
more breast cancer patients to receive breast-conserving
therapy [3–6]. Depending on the biological subtype of the
tumor, up to 60% of the patients achieve a pathological
complete response in the breast (bpCR) [7, 8]. The most
conservative definition of a bpCR was found to be a
complete disappearance of invasive and in situ residual
tumor disease in the breast (ypT0) [9–11].
Achieving a bpCR is a predictor for an improved disease
free and overall survival, and it is used as a surrogate clin-
ical endpoint for long term outcome [1, 4, 6, 10–16]. Only
mediocre diagnostic accuracy can be reached when pre-
dicting a bpCR before surgery by a combination of mul-
tiple aspects such as tumor biology, the applied NACT
regimen, and breast imaging results [8, 17–20].
Due to this diagnostic uncertainty, surgery after NACT
is considered to be obligatory for all patients in order to
either completely remove residual disease in non-bpCR
cases or to diagnose a bpCR [21]. So far, surgery is the
only valid diagnostic instrument to diagnose a bpCR.
However, there is evidence that in cases of a shrinking
tumor a less radical breast surgery is oncologically safe.
[22]. The case of a clinical or imaging complete response
(cCR), however, requires the diagnostic resection of (parts
of) the initial tumor bed in order to confirm (or not) a
possible bpCR histologically [6, 23].
Methods/design
Aims
The main purpose of this trial is to evaluate the accuracy
of a vacuum-assisted biopsy (VAB) for a reliable diagnosis
of a bpCR after NACT. The study is designed to prove the
false negative rate of the VAB is below 10% (= sensitivity is
90% or above).
Design
This study is designed as a multicenter, confirmative,
one-armed, intra-individually-controlled, open, diagnostic
trial. Patients will be recruited in 21 centers in Germany.
Participants
Participants are female patients aged 18 years and older
with primary breast cancer after NACT treatment which
has been performed for at least 12 weeks and resulted in
cPR or cCR (see below). Patients can be enrolled if the fol-
lowing inclusion criteria are met: any cT and cN stage, ex-
cept cT4 stages; patient is scheduled to undergo any
routine breast cancer surgical intervention planned accord-
ing to guidelines (breast conservation or mastectomy); the
residual intramammary target lesion or clip marker is vis-
ible in mammography and / or ultrasound; diagnosis of im-
aging complete or partial response according to RECIST
1.1 by mammography or ultrasound, according to local
routine; in case of multicentric disease: confirmation of the
same tumorbiological subtype of tumor defined by immu-
nohistology in at least 2 lesions. Only one breast per patient
will be included, in bilateral cancer one breast can be in-
cluded. Patients have to be able to understand the character
and individual consequences of the clinical trial and must
give written informed consent before enrollment in the
trial. Patients will be excluded from the trial in case of pal-
liative or recurrent breast cancer. Further exclusion criteria
are dislocation of clip marker (> 5 mm distance to the ini-
tial target lesion border at the time of clip placement),
contraindication for VAB or associated procedures (e.g.
local anesthesia) as well as pregnancy and lactation.
Intervention
In this study design the control (breast surgery = reference
test) and the comparator (VAB= index test) will both be
performed on every patient. After an initial screening visit
(visit 1), during which inclusion criteria will be checked and
informed consent will be obtained, the VAB will be per-
formed (visit 2). This intervention visit may vary by patient,
tumor, and trial site characteristics and may either be an
ultrasound guided or a stereotactically guided VAB. In ana-
logy to the German S3 guideline on primary breast cancer
management, we recommend to take at least 12 biopsies
with 10G needles or less in case of larger needle sizes [24],
bearing in mind that the probability of a sampling error
might be reduced by taking more samples. As quantification
of the specimen is not easily possible during the VAB
(weight, as well as the number of biopsies taken does not
necessarily quantify the amount of adequate tissue), we
propose to take as many samples as reasonably justifiable
(according to the local investigator). The VAB will be
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performed according to standards in primary breast diag-
nostics and according to the above mentioned guidelines.
The intervention may be performed before surgery at a sep-
arate visit, the day before surgery (e. g. during the wire loca-
tion), or in the operation room immediately prior to surgery
depending on the site specific organizational setting. As the
surgery will be performed according to clinical routine, there
is no specific time frame for each trial visit. The physician
performing the biopsy will be asked to quantify subjectively
the level of representativeness of the biopsy (secondary out-
come measure). The imaging performed during VAB may
not be used for assessment of inclusion/exclusion criteria.
Specimen radiography may be applied as an optional pro-
cedure after VAB to assess the representativeness of the
specimen radiologically (secondary outcome measure).
Standard surgery is regarded as the third trial visit (visit 3)
as standard surgical excision (either breast conserving sur-
gery or mastectomy) is the reference test. Adverse events
will be documented until the end of visit 3.
Adverse events
Possible adverse events of the VAB procedure may occur
while the biopsy is taken. Due to the simple study design
following clinical routine, very few adverse events are ex-
pected. Within the pilot study [25] there were no safety is-
sues. As the biopsy is an additional minimal invasive
intervention, it is accompanied by a number of possible
risks. Those include bleeding with (1) hematoma and (2)
possible urgent surgical intervention, infection, and injuries
of surrounding tissue. Theoretically, VAB could challenge
the surgeon, e. g. due to a hematoma and may lead to limi-
tations in reliably assessing (3) the final tumor size or (4)
the resection margins by pathology. The first two are in-
formative but not critical; the latter situations are also pos-
sible even without preoperative VAB but should not exceed
10% of the patients (ypTx </= 10% and final R1 / Rx status
</= 10%). We propose to interrupt the study as soon as
those cases exceed 10% of the whole cohort.
Intervention assignment and blinding
There will be no randomization within this one-armed
study design.
To be able to transfer the results to future management
concepts (e. g. omitting surgery in cases of VAB – proven
bpCR) the histopathological, study specific evaluation of
the VAB specimen will be performed independently of the
routine diagnostic evaluation. Nevertheless, the local path-
ologist will have access to information on pre-NACT
histopathological result, cT stage, ycT stage, estrogen re-
ceptor status, progesterone receptor status, Her2neu sta-
tus, grading, and ki-67 status (if available). However, she /
he will not receive any information regarding post-NACT
surgical specimen results. All pre-surgical variables should
be available and included in the pathological evaluation of
the VAB specimen after NACT. The interdisciplinary team,
including the breast surgeon as well as the patient, will also
be blinded to pathological results of the VAB specimen
until the final pathological report of the surgical specimen.
This will ensure an unbiased surgical intervention.
Pathological work-up of VAB specimens will be per-
formed in analogy to the primary diagnostic setting of sus-
picious breast lesions [26]. In order to achieve consistency
among pathologists regarding the criteria for evaluation of
the VAB specimen, a standard operating procedure will be
provided as well as a the possibility of using a reference pa-
thologist’s second opinion.
The pathological results of the VAB specimen will be
categorized as follows:
Category
A
Residual tumor cells in VAB specimen (= non-bpCR)
Category
B
No residual tumor cells in the VAB specimen and VAB
representative of former tumor region (= bpCR in VAB)
Category
C
No residual tumor cells in the VAB specimen but VAB
unclear representative or not representative of former tumor
region (= possible sampling error)
Category C VABs are categorized as uninformative for
the primary endpoint of the clinical trial.
The investigators assume that there is no difficulty
to diagnose a “Category A” VAB result. The
challenging topic is defining a VAB specimen to be
pathologically representative of the former tumor region
(tumor bed) or not, i. e. to differentiate between “Category
B” and “Category C”. Only representative VAB samples are
informative.
To evaluate intra- and interrater reliability of pathological
evaluation of VAB specimen all local pathologists will be
asked to send pre-NACT biopsy specimen and post-NACT
VAB specimen (H&E sections or virtual microscopy files)
of all non-tumorous VABs to the Department of Pathology
Heidelberg (“pathological sub-study”). Slides will be digi-
tized, pseudonymized, and returned to different local pa-
thologists. Intra- and interrater reliability evaluation will be
performed by at least five pathologists participating in the
trial.
Outcomes and measurements
The primary outcome is the false negative VAB result, i.e.
the non-detected residual tumor by VAB compared to
breast surgery. We will report this outcome as the false
negative rate (FNR= rate of patients with non-detected re-
sidual tumor by VAB compared to breast surgery) which is
a commonly used and validated measure in diagnostic stud-
ies. The FNR will serve as outcome measure in the cohort
of the confirmatory primary outcome analysis. It will be cal-
culated as the quotient of the number of cases with bpCR
in VAB (“Category B”) and residual tumor in surgical
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specimen (false negative VAB results), divided by the total
number of cases with residual tumor in either specimen
(VAB and / or surgical specimen). Residual tumor is de-
fined as a positive result, in surgical specimen as well as in
VAB.
As our secondary outcomes we will use true negative
and true positive results compared to breast surgery.
The standard definitions are applied.
Statistical procedures
Sample size calculation
As the primary endpoint we use the rate of patients with
non-detected residual tumor (=false negative cases), the
sample size calculation refers to the required number of
patients for which surgery revealed a residual tumor.
This number depends on the prevalence of residual
tumor in the whole cohort. Motivated by previous works
and the definition of the inclusion and exclusion criteria,
we assume that this prevalence is at least 0.5. For the test
hypotheses the sample size required to achieve a power of
0.8 is given by 238 cases (calculated with the software
ADDPLAN Version 6.1.1). Consequently, a total of 476 pa-
tients have to be recruited to reach the required number of
cases with residual tumor. As the prevalence of 0.5 is only
an estimator and, moreover, some patients may be excluded
from the analysis because of an unclearly representative
VAB, we add an exclusion rate of 0.25 according to the
findings in the pilot study [25]. This results in a total num-
ber of 595 patients, which will be rounded up to 600 pa-
tients, to be assigned to the trial.
Analysis variables
Derivation of the primary endpoint
The false negative rate (FNR) will be calculated as the
quotient of the number of cases with “pCR in VAB” and
residual tumor in surgical specimen (false negative VAB
results), divided by the total number of cases with residual
tumor in surgical specimen and / or VAB in the cohort of
the confirmatory primary outcome analysis (= primary
analysis set).
Derivation of secondary endpoints
Specificity, negative, and positive predictive values will be
calculated according to the standard definitions.
Primary analysis set
This data set defines the cohort of patients based on which
the primary confirmatory efficacy analysis is performed.
The primary analysis set consists of all recruited patients
excluding those with a pathologically defined uninformative
VAB sample tissue (“Category C”: unclear representative or
not representative VAB).
Secondary analysis set
The Secondary Analysis set consists of all recruited patients
including those with an unclear representative or not
representative VAB sample tissue in the histopathological
assessment. This data set defines the cohort of patients and
subsamples based on which the secondary descriptive
analyses are performed (see below “Secondary Analysis”).
Analysis strategy
Primary efficacy analysis
The null hypothesis to be assessed within the confirmatory
analysis states that the rate of patients with non-detected re-
sidual tumor p is larger or equal to 0.1. Whereas the alter-
native hypothesis, for which this trial is powered, states that
p is at most 0.05. The test hypotheses are thus given by.
H0: p ≥ 0.1 versus H1: p < 0.05,
which are tested with the one-sample Binomial-test at
a one-sided significance level of α = 0.025.
The rate of patients with non-detected residual tumor
p is estimated by the number of cases with diagnosed
bpCR in VAB divided by the number of all patients for
which surgery or VAB revealed a residual tumor.
Secondary analyses
All secondary endpoints are evaluated descriptively for the
Primary Analysis Set (all recruited patients excluding
“Category C”) as well as the Secondary Analysis Set (all
recruited patients including “Category C”) in order to allow
comparability and evaluation of the histopathological
analysis. The secondary endpoints will be evaluated for the
whole cohort and for six subgroups defined by.
(1) the tumor biology (TNBC, HER2+, and HR
+/HER2-)
(2) the clinical / imaging response assessment (cCR,
near cCR, cPR)
(3) the assessment of representativeness by specimen
radiography.
(4) the subjective rating of the physician performing
the biopsy.
(5) the different hospitals taking part in the study.
(6) the guidance method of the minimal invasive biopsy
(ultrasound / stereotactic)
The investigators will provide point estimators and
corresponding 95% confidence intervals for sensitivity,
specificity, and diagnostic odds ratios for bpCR. Predictive
values are obtained by using Bayes’ theorem based on the
different prevalence estimates for bpCR in the full cohort,
the subgroups mentioned above, and the trial centers.
The pathological evaluation of the VAB specimen
(“pathological sub-study”, see above) will be assessed using
Cohen’s Kappa where satisfactory agreement will be defined
as an observed value of > / = 0.7.
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Absolute and relative frequencies of adverse events are
provided together with 95% confidence intervals.
We plan to perform an interim data look after having
recruited and fully documented 300 participants. Within
this interim look, no early testing for efficacy will be
performed. However, it will be evaluated if a stop for futility
seems indicated. A stop for futility could be indicated if the
number of false negative cases is too large to reach the
study aim (non-stochastic curtailment) or for other safety
reasons.
Discussion
To date, there are a number of closed, ongoing, and
planned trials on this subject, described elsewhere in
detail [27]:
As we do not know the maximum sampling error
(= FNR) without impairing loco-regional control rates
in case of omitting surgery, we deduced a maximum
FNR of 10% from the results of the sentinel node tri-
als. In these studies a false negative rate of 10% did
not translate into a worse loco-regional or overall sur-
vival [28]. More recently, the ACOSOG Z0011 trial
showed, that leaving lymph node metastases behind in
about 20% of the cases, did not translate into worse
loco-regional, disease-free and overall survival [29]. As the
cohort of patients treated with NACT is a high risk popu-
lation we decided for a reasonably low FNR.
During the study we anticipate a set of possible
challenges in patient recruitment. First of all, the VAB
intervention does not provide participating patients with a
personal benefit. By contrast, it involves a second invasive
intervention in addition to surgery. We thus assume
patients to be reluctant to participate in the study. Hence, a
proficient informed consent discussion with the patient and
a detailed explanation of the study aim will be crucial for
patient recruitment.
Another critical issue in VAB evaluation will be the
histopathological evaluation of the representativeness of the
VAB specimen. Differentiating accurately between a
Category B (= pCR in VAB) and Category C (= possible
sampling error) result will be decisive for the achievement
of qualified study results. In the pilot study [25] anticipating
this RESPONDER trial, the following stroma and cell
reactions were used as criteria based on preceding reports
[30–32]. Typical stroma reactions due to NACT included
oedematous swelling or fibrosis. Within the fibrotic area a
low cell-density was found. Stroma cell reactions were con-
stituted of atypical adenoid cell complexes with large nuclei,
regressively transformed residuals of atypical ductal epithe-
lial proliferation, atypical ductal epithelial hyperplasia, or
metaplasia of cylindrical cells. Furthermore, cell reac-
tions included macrophage reactions such as the
presence of foam cell-like macrophages, giant cells,
hemosiderin-charged macrophages, or foam cells indicating
resorptive processes. Round cell infiltrates and lympho-
histiocytic inflammatory infiltrates were partly present.
Based on these findings and experiences histopathological
evaluation should allow a standardised diagnostic
categorisation.
In case of study results which would permit rejection
of the null hypothesis by yielding a false negative rate of
less than 10%, VAB would be rated as an accurate
diagnostic measure. Possible future trial scenarios would
raise difficult questions: In this still hypothetical setting,
studies on the therapeutical impact of surgery in bpCR
cases would be the consistent consequence. However,
the possible setting in which such a study could be
realized remains unclear. Ethical and technical issues
will have to be addressed for future trial designs. One
future option might be a two-armed randomized con-
trolled trial with radiotherapy only as local therapeutic
management as one arm and surgery (with or without
radiotherapy according to guidelines) as the other arm.
Potential endpoints of such a trial might be disease free
or in-breast recurrence free survival. Recruitment may
be a challenge in a trial offering a non-surgical treatment
arm. However, sooner or later the planning of possible
future clinical trials on the omission of surgery in bpCR
cases will have to be discussed.
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